Total Flavonoids Isolated from Can Alleviate Bone Loss and Regulate Intestinal Microbiota in Ovariectomized Rats

Overview

Journal Front Pharmacol

Date 2025 Feb 24

PMID 39989899

Authors

Baocang Yin

Mingzhen Yang

Bowen Wang

Yun Zhang

Ningli Li

Qin Li

Yingying Li

Cory J Xian

Tiejun Li

Yuankun Zhai

Affiliations

Soon will be listed here.

Abstract

Ethnopharmacological Relevance: , recognized as a traditional Chinese medicinal herb, can tonify liver and kidney and strengthen bones and muscles. Modern pharmacological research has proved that could prohibit the occurrence of osteoporosis and arthritis.

Aim: To investigate the effect and action mechanism of total flavonoids isolated from the leaves of (TFEL) on bone loss in ovariectomized (OVX) rats, and to study its effect on intestinal flora.

Materials And Methods: The 3-month-old female rats were randomly divided into six groups: sham operation group, OVX model group, estradiol group, TFEL low (TFEL-L) (50), mid (-M) (100) and high (-H) (200 mg/kg/d) dose groups. After 13 weeks of treatment, the rats were sacrificed to measure bone turnover markers, related tissue biochemical indices, microstructure parameters, and osteoclastogenesis promotor RANKL and inhibitor OPG expression levels. Additionally, fecal samples were obtained for high-throughput sequencing to analyze the intestinal flora.

Results: Oral administration of TFEL for 13 weeks increased the serum level of bone formation marker PINP and decreased the level of bone resorption marker NTX-I. The femoral microstructure parameters of the TFEL-M and TFEL-H groups were significantly improved compared with the OVX group, which were also confirmed by H&E histological staining. High-throughput sequencing indicated that TFEL may regulate the composition of intestinal flora and intestinal microecology.

Conclusion: TFEL can prevent osteoporosis in OVX rats and has no toxic side effects. Meanwhile, TFEL can increase the diversity and improve the composition of intestinal flora in OVX rats.

References

Deyama T, Nishibe S, Nakazawa Y . Constituents and pharmacological effects of Eucommia and Siberian ginseng. Acta Pharmacol Sin. 2001; 22(12):1057-70. View

Shin H, Kwak S, Lee J, Zhang D, Bae J, Song W . Exercise, the Gut Microbiome, and Frailty. Ann Geriatr Med Res. 2020; 23(3):105-114. PMC: 7370771. DOI: 10.4235/agmr.19.0014. View

Ohlsson C, Sjogren K . Effects of the gut microbiota on bone mass. Trends Endocrinol Metab. 2014; 26(2):69-74. DOI: 10.1016/j.tem.2014.11.004. View

Song S, Guo Y, Yang Y, Fu D . Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther. 2022; 237:108168. DOI: 10.1016/j.pharmthera.2022.108168. View

Zhang Y, Yang M, Li N, Li Q, Li Y, Zhai Y . Total Flavonoids Isolated from the Leaves of Augment Peak Bone Mass in Female Rats and Show no Side Effects in Other Organs. Curr Pharm Des. 2024; 30(30):2410-2423. DOI: 10.2174/0113816128298755240613100018. View

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

Diab D, Watts N . Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2013; 20(6):501-9. DOI: 10.1097/01.med.0000436194.10599.94. View

Chen X, Wang Z, Duan N, Zhu G, Schwarz E, Xie C . Osteoblast-osteoclast interactions. Connect Tissue Res. 2017; 59(2):99-107. PMC: 5612831. DOI: 10.1080/03008207.2017.1290085. View

Fuhrman B, Feigelson H, Flores R, Gail M, Xu X, Ravel J . Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014; 99(12):4632-40. PMC: 4255131. DOI: 10.1210/jc.2014-2222. View

10.

He X, Wang J, Li M, Hao D, Yang Y, Zhang C . Eucommia ulmoides Oliv.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol. 2013; 151(1):78-92. DOI: 10.1016/j.jep.2013.11.023. View

11.

Ostrowska Z, Ziora K, Oswiecimska J, Swietochowska E, Szapska B, Wolkowska-Pokrywa K . RANKL/RANK/OPG system and bone status in females with anorexia nervosa. Bone. 2011; 50(1):156-60. DOI: 10.1016/j.bone.2011.09.054. View

12.

Ma S, Qin J, Hao Y, Shi Y, Fu L . Structural and functional changes of gut microbiota in ovariectomized rats and their correlations with altered bone mass. Aging (Albany NY). 2020; 12(11):10736-10753. PMC: 7346027. DOI: 10.18632/aging.103290. View

13.

Rizzoli R . Nutritional influence on bone: role of gut microbiota. Aging Clin Exp Res. 2019; 31(6):743-751. DOI: 10.1007/s40520-019-01131-8. View

14.

Wu D, Cline-Smith A, Shashkova E, Perla A, Katyal A, Aurora R . T-Cell Mediated Inflammation in Postmenopausal Osteoporosis. Front Immunol. 2021; 12:687551. PMC: 8278518. DOI: 10.3389/fimmu.2021.687551. View

15.

Huang L, Lyu Q, Zheng W, Yang Q, Cao G . Traditional application and modern pharmacological research of Eucommia ulmoides Oliv. Chin Med. 2021; 16(1):73. PMC: 8349065. DOI: 10.1186/s13020-021-00482-7. View

16.

Eastell R, Szulc P . Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017; 5(11):908-923. DOI: 10.1016/S2213-8587(17)30184-5. View

17.

Seely K, Kotelko C, Douglas H, Bealer B, Brooks A . The Human Gut Microbiota: A Key Mediator of Osteoporosis and Osteogenesis. Int J Mol Sci. 2021; 22(17). PMC: 8431678. DOI: 10.3390/ijms22179452. View

18.

Yan J, Charles J . Gut Microbiome and Bone: to Build, Destroy, or Both?. Curr Osteoporos Rep. 2017; 15(4):376-384. PMC: 5538387. DOI: 10.1007/s11914-017-0382-z. View

19.

Zhai Y, Wang Q, Li Y, Cui J, Feng K, Kong X . The higher osteoprotective activity of psoralidin in vivo than coumestrol is attributed by its presence of an isopentenyl group and through activated PI3K/Akt axis. Biomed Pharmacother. 2018; 102:1015-1024. DOI: 10.1016/j.biopha.2018.03.166. View

20.

Wang Y, Tan X, Li S, Yang S . The total flavonoid of sensitizes human glioblastoma cells to radiotherapy via HIF-α/MMP-2 pathway and activates intrinsic apoptosis pathway. Onco Targets Ther. 2019; 12:5515-5524. PMC: 6633463. DOI: 10.2147/OTT.S210497. View